The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides

Affiliations

¹ 2nd Department of Dermatology and Venereology, School of Medicine, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
² 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece.
³ Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁴ Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁵ 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University of Athens Medical School, "Andreas Sygros" Hospital for skin diseases, Athens, Greece.

A Patsatsi et al. J Eur Acad Dermatol Venereol. 2022 Apr.

. 2022 Apr;36(4):e291-e293.

doi: 10.1111/jdv.17795. Epub 2021 Nov 23.

¹ 2nd Department of Dermatology and Venereology, School of Medicine, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
² 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece.
³ Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁴ Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁵ 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University of Athens Medical School, "Andreas Sygros" Hospital for skin diseases, Athens, Greece.

No abstract available

References

1. Trautinger F, Eder J, Assaf C et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer 2017; 77: 57-74.
1. Hüsken AC, Tsianakas A, Hensen P et al. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatology Venereol 2012; 26: 71-78.
1. Schiller M, Tsianakas A, Sterry W et al. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2017; 31: 1841-1847.
1. Fujimura T, Okuyama R, Hashimoto A et al. Effective control of rush progression of CD8+ mycosis fungoides with pegylated interferon. Acta Derm Venereol 2006; 86: 161-162.